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Abstract
Background: Bronchopulmonary dysplasia (BPD) is the most common complication of preterm birth with short-term
and long-term adverse consequences. Although the glucocorticoid dexamethasone has been proven to be beneficial
for the prevention of BPD, there are concerns about an increased risk of adverse neurodevelopmental outcome.
Hydrocortisone has been suggested as an alternative therapy. The aim of the Systemic Hydrocortisone To Prevent
Bronchopulmonary Dysplasia in preterm infants (SToP-BPD) trial is to assess the efficacy and safety of postnatal hydrocortisone
administration for the reduction of death or BPD in ventilator-dependent preterm infants.
Methods/design: The SToP-BPD study is a multicentre, double-blind, placebo-controlled hydrocortisone trial in preterm
infants at risk for BPD. After parental informed consent is obtained, ventilator-dependent infants are randomly allocated
to hydrocortisone or placebo treatment during a 22-day period. The primary outcome measure is the composite outcome
of death or BPD at 36 weeks postmenstrual age. Secondary outcomes are short-term effects on pulmonary condition and
long-term neurodevelopmental sequelae assessed at 2 years corrected age. Complications of treatment, other serious
adverse events and suspected unexpected serious adverse reactions are reported as safety outcomes. This pre-specified
statistical analysis plan was written and submitted without knowledge of the unblinded data.
Trial registration: Netherlands Trial Register, NTR2768. Registered on 17 February 2011. EudraCT, 2010-023777-19.
Registered on 2 November 2010.
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Background
Bronchopulmonary dysplasia (BPD) is the most common
complication of preterm birth [1–3]. Pulmonary inflamma-
tion has been identified as an important risk factor in the
development of BPD, providing the rationale for treating
patients at risk for BPD with glucocorticoids, a group of
drugs well known for their strong anti-inflammatory effect
[4]. Randomised controlled trials (RCTs) comparing dexa-
methasone with placebo in ventilated preterm infants at
risk for BPD have shown that dexamethasone reduces the
incidence of the composite outcome of death or BPD [5, 6].
Unfortunately, follow-up studies showed associations with
adverse neurodevelopmental outcome [5]. Therefore, inter-
national guidelines have stated that the use of dexametha-
sone should be restricted to exceptional cases (i.e., patients
who cannot be weaned off the ventilator), and clinical trials
should be performed to investigate the efficacy and safety
of alternative anti-inflammatory glucocorticoids such as
hydrocortisone (HC) to prevent BPD [7, 8].
The Systemic Hydrocortisone To Prevent Bronchopul-
monary Dysplasia in preterm infants (SToP-BPD) study is
the first multicentre, placebo-controlled, double-blind
RCT investigating the efficacy and safety of systemic HC
initiated between 7 and 14 days after birth in mechanically
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ventilated preterm infants. The study protocol was pub-
lished previously [9]. This paper describes the final statis-
tical analysis plan (SAP) in detail. This SAP was written
and submitted without knowledge of the unblinded data.
Objectives
The primary aim of the SToP-BPD trial is to investigate
if systemic HC started between 7 and 14 days after birth
is effective and safe in reducing the incidence of the
composite outcome of death or BPD at 36 weeks post-
menstrual age (PMA) in chronically ventilated preterm
infants, as compared with a placebo (primary endpoint).
Methods/design
Design and setting
The SToP-BPD study is a multicentre, phase III, placebo-
controlled, double-blind superiority trial in mechanically
ventilated preterm infants at risk for BPD, performed in 19
neonatal intensive care units (NICUs) in the Netherlands
and Belgium.
Study protocol development and conduct
The SToP-BPD study is registered with the Netherlands
Trial Register (NTR2768; registered on 17 February 2011)
and the European Union Clinical Trials Register (EudraCT,
2010-023777-19; registered on 2 November 2010). The
ethics committee of the Academic Medical Centre in
Amsterdam approved the study protocol on 28 January
2011, starting with ten Dutch and five Belgian NICUs. Four
Belgian NICUs joined the study at a later date. The local
ethics committee of each participating hospital approved
the local feasibility of the study protocol. During the course
of the study, the accredited ethics committee approved two
amendments regarding changes of the inclusion criteria
(see below). The trial was conducted according to the prin-
ciples of the Declaration of Helsinki, Dutch and Belgium
legislation regarding medical research involving human
subjects [10–13], and good clinical practice (GCP) guide-
lines [14]. Patients could be included in the trial only after
written informed consent from both parents was obtained.
All study sites were monitored by an independent clinical
research associate of the Academic Medical Centre Clinical
Research Unit (Amsterdam, the Netherlands). An inde-
pendent data and safety monitoring board (DSMB) moni-
tored the study’s progress, with a special focus on safety
(see below). The trial will be reported according to the
Consolidated Standards of Reporting Trials (CONSORT)
guidelines [15].
Inclusion and exclusion criteria are described in the
published study protocol [9]. Ventilator-dependent pre-
term infants (gestational age < 30 weeks and/or birth
weight < 1250 g) at high risk of developing BPD were in-
cluded between 7 and 14 days postnatal age (PNA). The
risk of developing BPD was assessed by the respiratory
index (RI), defined as the product of mean airway pres-
sure (MAwP) and the fraction of inspired oxygen (FiO2).
In the absence of firm evidence, a high risk of developing
BPD was arbitrarily defined as an RI ≥ 3.5 for > 12 h/day
for ≥ 48 h, ensuring adequate oxygen saturation (85–95%)
and partial pressure of carbon dioxide values (5.0–7.5
kPa). However, during the first months of the trial, the
participating centres found that this arbitrarily chosen RI
cut-off of 3.5 was too high. The centres noted that many
infants ventilated between 7 and 14 days PNA with an RI
< 3.5 were still at high risk of developing BPD, as indicated
by the fact that most of these infants were treated with
corticosteroids outside the trial. Therefore, the RI thresh-
old in the inclusion criteria was reduced stepwise, first to
3.0 (21 May 2012) and finally to 2.5 (3 December 2012), to
make sure that all infants at high risk of BPD could be
included in the study. Both RI adjustments were submit-
ted as protocol amendments to the accredited ethics
committee and approved.
Included participants were allocated to either HC or
placebo treatment according to the study protocol. In
general, the use of open-label HC during the 22-day
treatment course was strongly discouraged. However,
open-label HC use was allowed if the patient met the
predefined criteria described in the study protocol [9].
The open-label HC dosage schedule was similar to that
used in the study. The study medication was stopped
when open-label HC was initiated. Patients receiving
open-label HC were followed in the same way as all
other patients.
Randomisation and data collection
Eligible patients were randomly allocated in a 1:1 ratio
to either HC or placebo, stratified by centre and gesta-
tional age [9]. To ensure allocation concealment, the
randomisation sequence was generated by using fully
GCP- and U.S. Food and Drug Administration-
compliant ALEA® randomisation software (www.formsvi-
sion.com; ALEA Clinical/FormsVision, Abcoude, the
Netherlands). Randomisation was centrally controlled
and web-based, using a dedicated, password-protected,
SSL-encrypted website. The infants’ parents, all mem-
bers of the research team, and the medical team
remained blinded to group assignment throughout the
study. Data management was implemented according to
GCP guidelines. Patient data until hospital discharge and
long-term follow-up data are entered via an electronic
case record form in a central GCP proof web-based
database to facilitate on-site data entry (Oracle® Data-
base Reference 12c Release 1 [12.1]; Oracle, Redwood
Shores, CA, USA), as described in the study protocol
[9]. Security is guaranteed with login names, login codes
and encrypted data transfer.
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Primary outcome
The primary outcome is the dichotomous composite
outcome of death or BPD at 36 weeks PMA (BPD-free
survival). Patients were categorised as having BPD when
needing supplemental oxygen and/or positive pressure
support at 36 weeks PMA, assessed according to the
Eunice Kennedy Shriver National Institute of Child Health
and Human Development Consensus Statement using the
classification of severity as proposed by Jobe et al. [4] and,
if indicated, the oxygen reduction test as described by
Walsh et al. [16, 17].
Secondary outcomes
Study phase I: short-term outcomes before initial
hospital discharge Secondary efficacy outcomes assessed
during the study phase before initial hospital discharge in-
clude mortality (at 28 days PNA, 36 weeks PMA and hos-
pital discharge), BPD (at 28 days PNA and 36 weeks PMA,
including severity grade), failure to extubate (at 3, 7, 14 and
21 days after initiating study medication), total duration of
mechanical ventilation, total time receiving supplemental
oxygen, use of open-label HC treatment, hospital length of
stay, necrotising enterocolitis (NEC) with Bell stage II or
higher [18], gastrointestinal bleeding, spontaneous intestinal
perforation (SIP), intraventricular haemorrhage (IVH) and/
or periventricular leucomalacia (PVL) [19], retinopathy of
prematurity (ROP) [20], hypertension, hyperglycaemia
requiring the use of insulin therapy, nosocomial infection
including clinical or culture-proven sepsis, meningitis and
pneumonia, patent ductus arteriosus for which medical
intervention or surgical ligation is needed, and growth
(weight, head circumference, and length at 36 weeks PMA).
Study phase II: long-term follow-up outcomes at 2
years corrected age Neurodevelopmental impairment at
2 years corrected age (CA) will be assessed according to
the cognitive and motor composite scores of the Bayley
Scales of Infant and Toddler Development, Third Edition
(BSID III) [21]. Norm value of BSID III scores is 100 (SD
15), with higher values indicating better function. Other
secondary outcomes are: mortality, number of hospital
readmissions since first discharge home, cerebral palsy
and its severity assessed by the gross motor function
classification system [22], hearing loss requiring hearing
aids, blindness, behavioural problems (Child Behavior
Checklist [23]), weight, length and head circumference.
Safety
Safety outcomes were classified as follows:
1. Complications of HC treatment (see “Secondary
outcomes: Study phase I: short-term outcomes
before initial hospital discharge” subsection above);
2. Suspected unexpected serious adverse drug reactions
(SUSARs); and
3. Other serious adverse events (SAEs).
Statistical methods specified in the study protocol
Sample size calculation
As described in the study protocol, the a priori risk of
death or BPD in preterm infants < 30 weeks gestation
and ventilated in the second week of life is estimated at
60–70% [9]. Authors of a meta-analysis of moderately
early dexamethasone treatment estimated an absolute
risk reduction (ARR) of 25% (number needed to treat
[NNT] = 4) compared with placebo [24]. No data are
currently available on the efficacy of HC, and the sug-
gested cumulative dose in the present study is consider-
ably lower than previously used dexamethasone doses.
Because the efficacy of dexamethasone is dependent on
the doses used [25, 26], we proposed a more conserva-
tive approach, defining an ARR of ≥ 15% (NNT = 7) as
clinically relevant and still approaching the reported effi-
cacy of dexamethasone.
If the probability of death or BPD at 36 weeks PMA is
0.60 in the placebo arm and 0.45 in the HC group, then
including 175 patients in each group (total 350, chi-
square test without continuity correction) and a two-
tailed type I error of 0.05 will result in a power of 80%
(Statistical Solutions Ltd., Cork, Ireland). We anticipated
that ~ 10% of patients would drop out of the study and
hence aimed to include 200 patients in each treatment
arm (total 400).
Originally proposed analyses
In the previously published protocol [9], the originally
proposed analyses are described, including both an
intention-to-treat (ITT) and per-protocol (PP) analysis
because use of open-label glucocorticoids may modulate
possible treatment effects. The effect of HC on the
primary outcome of BPD-free survival is assessed by
multivariable logistic regression analysis including pos-
sible confounders. p Values < 0.05 are viewed as statisti-
cally significant. Below we present the final and further
detailed SAP.
Interim analyses and safety reporting
A DSMB was installed for this study to protect patients and
to assist and advise the principal investigator in protecting
the safety, validity and credibility of the trial. Members
included a clinically experienced paediatric pulmonologist,
a paediatric intensivist-clinical pharmacologist with exten-
sive knowledge of the use of drugs in infants, and a biostat-
istician. The members were not involved in the trial and
had no competing interests. The composition, tasks,
responsibilities and working procedures of the DSMB were
described in a charter.
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In the first 2 years of the study, interim analyses for
safety issues were performed every 3 months. After this
period, the frequency of safety monitoring was reduced
to thrice and then twice annually, owing to the decreas-
ing recruitment rate. The DSMB received a report before
every interim analysis prepared by the trial statistician
that included data on baseline variables (gestational age,
birth weight, sex, multiple births), the primary outcome
parameter, predefined safety outcomes, and SAEs and
SUSARs. In the closed session, attended only by the
DSMB members, the DSMB examined the data using
coded (blinded) treatment groups. If necessary, treat-
ment allocation could be unblinded.
The DSMB charter stated that there were two
possible reasons for stopping the study early, namely
concerns for safety and futility. In principle, the trial
was not to be stopped early for beneficial effect of HC
treatment on the primary outcome before the mini-
mum number of evaluable patients required (350) was
included. This was done to preserve the power for
evaluation of neurodevelopmental outcome at 2 years
CA, unless HC benefit was accompanied by an
unacceptably high rate of mortality in the placebo
group. Hence, there was no alpha spending associated
with the interim analyses.
Regarding safety, the study would be stopped at an
interim analysis if one or more of the following safety
issues occurred and a two-sided p value < 0.10 (blinded
analyses) or a one-sided p value < 0.05 (unblinded ana-
lyses) was obtained:
 Mortality was ≥ 10% higher in the HC group than
in the placebo group
 Combined NEC Bell stage III and SIP ≥ 10% higher
in the HC group than in the placebo group
 ROP stage III or higher ≥ 10% higher in the HC
group than in the placebo group
 PVL stage I or higher ≥ 5% higher in the HC group
than in the placebo group
In addition, the study would be stopped following
50% or 75% of planned inclusion if the primary out-
come (composite endpoint of mortality or BPD at 36
weeks PMA) was ≥ 15% higher owing to ≥ 10% higher
mortality in the placebo group than in the HC group.
If the difference in the primary outcome between the
placebo and HC groups was < 10% following 75% of
the planned inclusion, the trial was to be stopped for
futility. All differences in percentages between the
groups defined in the DSMB charter were absolute dif-
ferences. If one or more of these situations occurred,
the clinical relevance, reliability and consistency of the
results were incorporated into the decision whether to
end the trial prematurely.
Statistical analysis plan
Overall principles
The first phase of data analysis and reporting will
include all outcome data up to discharge to home. Ana-
lysis will start once all data to discharge of the last
included patient have been obtained, the database has
been cleaned and locked, and the SAP has been submit-
ted for publication. The analyses will be performed by a
statistician and methodologist, neither of whom is
involved in the assessment of trial outcomes.
Analyses will be performed according to the ITT
principle. Given the modulating effects of open-label
corticosteroids [27], analyses will also be done in an as-
treated (AT) population and a PP population (see below)
to check the robustness of the main analyses. For all
relevant parameters, 95% CIs will be presented. p Values
< 0.05 will be regarded as statistically significant. For
statistical programming and analysis, we will use the
IBM SPSS Statistics version 24 statistical software pack-
age (IBM, Armonk, NY, USA) and the R environment
for statistical computing (R Foundation for Statistical
Computing, Vienna, Austria).
The statistician and methodologist will perform the ana-
lysis blinded to the allocated study treatment and using a
fictive randomisation code. After the data analyses have
been completed, they will be repeated using the true treat-
ment allocation. These analyses will be performed and
published before the assessment of long-term outcomes at
2 years CA of all included patients have been completed.
As in other trials in neonatology, it is deemed unethical to
withhold the results of the primary outcome analyses from
the international community for another 2 years.
This first phase of data analysis and reporting will be
followed by a second phase, analysing and reporting the
long-term neurodevelopmental outcomes after 2 years.
Clinicians involved in care during the initial hospitalisa-
tion, outcome assessors of the neurodevelopmental
outcome at 2 years CA, and parents will be kept blinded
to the treatment allocation of all included patients until
this second report has been published.
Handling of missing data
In case of missing data, every attempt will be undertaken to
retrieve the data. We will contact both levels III and II (re-
ferral) hospitals because many infants will be transferred
back to referral hospitals once clinically stable [4, 28].
Because the primary outcome will be assessed before
hospital discharge, we anticipate no or minimal missing
values. In case an oxygen reduction test is indicated but has
not been performed, a committee of three independent
experts will assess the severity of the BPD diagnosis. These
experts will be kept blinded to the allocation arm during
this assessment. Owing to frequent standard care follow-up
visits and strong relationships between physicians and the
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families of the preterm infants, we anticipate little missing
follow-up data. All cases lost to follow-up will be recorded,
including their available key characteristics and trial results
and reason for the loss to follow-up. Missing data will not
be imputed, with the exception of the long-term neurode-
velopmental outcomes [see “Long-term outcomes at 2 years
corrected age (study phase II)” section below.
Definition of analysis sets
Intention-to-treat population The ITT population
includes all randomised infants, regardless of protocol
deviations (see below) or use of open-label corticoste-
roids (Table 1). This includes patients with a signed in-
formed consent for the study who were randomised but
died before receiving the first dose of study medication.
As-treated population Infants will be analysed in
groups according to the actual treatment received (i.e.,
yes or no corticosteroids), regardless of allocated treat-
ment at randomisation (Table 1). Infants will still be
included in the AT population if there was a protocol
deviation (see below).
Per-protocol population In the PP population, all pa-
tients included and treated in accordance with the study
protocol will be included (Table 1). Patients allocated to
the placebo group but treated with open-label cortico-
steroid treatment in compliance with the study protocol
will be included in the PP placebo group. Infants in both
treatment groups treated with open-label corticosteroids
outside the study protocol or in whom other protocol
deviations (see below) occurred will be excluded from
the PP population.
Statistical analyses
Patient flow
The flow of participants is displayed in the CONSORT
flow diagram (Fig. 1). Reasons that eligible patients were
not included, such as parents declined consent or the
medical team did not ask the parents, will be summarised.
Protocol deviations
Protocol deviations are defined as deviations in eligibility
criteria and open-label corticosteroid treatment not con-
forming to conditions set forth in the study protocol, or
unblinding. All protocol deviations will be line-listed.
Baseline characteristics
We will present the following maternal characteristics: age,
ethnic origin, highest completed level of education, mode
of delivery, antenatal corticosteroids, chorioamnionitis, pre-
eclampsia and multiple pregnancy. We will also present the
following baseline characteristics of patients: gestational
age; sex; birth weight; small for gestational age; Apgar score
at 5 minutes; surfactant therapy; pulmonary air leak syn-
drome; patent ductus arteriosus; clinical and culture-
proven sepsis before randomisation; inhalation of nitric
oxide and hypotension, NEC, SIP and/or IVH before
randomisation; age at randomisation; and FiO2 MAwP at
start of study medication. All variables will be presented as
summary statistics according to allocation arm of the trial.
Continuous normally distributed variables will be sum-
marised using the mean and SD. Continuous non-normally
Table 1 Definition of population analysis sets
Analysis
population
HC treatment group Placebo treatment group
Intention to treat
‘as randomised’
HC randomisation:
• Including all protocol deviations (e.g., in eligibility criteria)
Placebo randomisation:
• Including all protocol deviations (e.g., in eligibility criteria)
As treated
‘actual
treatment’
Patient received HC (at least one dose), regardless of allocated
treatment at randomisation:
• Including those infants who received rescue open-label
corticosteroids as described according to protocol
• Including those infants who received rescue open-label
corticosteroids not following protocol (protocol deviation)
• Including those infants with other protocol deviations
(e.g., in eligibility criteria)
Patient received placebo (at least one dose), regardless of allocated
treatment at randomisation:
• Including those infants not receiving any corticosteroid dose
for pulmonary reasons
• Excluding those infants who received rescue open-label
corticosteroids following study protocol
• Excluding those infants who received rescue open-label
corticosteroids not following study protocol
• Including those infants with other protocol deviations (e.g., in
eligibility criteria)
Per protocol HC randomisation and treated according to study protocol:
• Including those infants receiving rescue open-label
corticosteroids as described by the study protocol
• Excluding those infants receiving rescue open-label
corticosteroids not according to study protocol
(protocol deviation)
• Excluding other protocol deviations (e.g., in eligibility
criteria)
Placebo randomisation and treated according to study protocol:
• Including those infants receiving rescue open-label corticosteroids
following study protocol
• Excluding those infants receiving rescue open-label corticosteroids
not following study protocol (protocol deviation)
• Excluding other protocol deviations (e.g., in eligibility criteria)
HC hydrocortisone
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distributed variables will be summarised using the median
and IQR. Categorical variables will be summarised using
counts and percentages. No formal testing will be per-
formed on the baseline characteristics.
Short-term outcomes until initial hospital discharge (study
phase I)
Primary outcome In Table 2, an overview is given of all
study outcomes with their planned analysis methods.
Crude estimates of the relative risk and ARR of the
primary outcome in the HC group compared with the
placebo group will be calculated. The main analysis of
the effect of HC on the primary outcome will be per-
formed using a logistic regression model, correcting for
the stratification factors gestational age (less than or
greater than or equal to 27 weeks) and centre. Adjusting
for stratification by centre can lead to problems with the
convergence or stability of estimates of statistical param-
eters if some or all centres are small [29]. To ensure that
the estimates of the regression parameters converge,
hospitals with fewer than ten subjects without and/or
fewer than ten subjects with the composite endpoint
BPD-free survival at 36 weeks PMA will be combined in
this analysis [30]. The effect sizes from this model will
be expressed as an adjusted OR.
In an additional analysis, the effect of HC on the
primary outcome will be evaluated using a multivariate
logistic regression model including five important
biologically plausible baseline risk factors for BPD, pre-
selected on the basis of literature and our clinical experi-
ence: (a) gestational age (less than or greater than or
equal to 27 weeks) [31], (b) the presence of chorioam-
nionitis [32], (c) RI at randomisation [33], (d) sex [34]
and (e) multiple pregnancy [35].
Sub-group analyses We will perform pre-specified ex-
ploratory sub-group analyses for the primary outcome
by examining treatment × sub-group interaction effects
in logistic regression models. We will perform six ana-
lyses, each examining one sub-group: gestational age
groups (less than or greater or equal to 27 weeks), pres-
ence of chorioamnionitis (yes/no), RI at randomisation,
sex (male/female), multiple pregnancy (yes/no) and
centre preference for type of steroid treatment prior to
the study (‘HC’ versus ‘dexamethasone’). Each of these
analyses will require four parameters to be estimated in
the logistic regression. If there are fewer than 40 patients
with and/or fewer than 40 patients without the compos-
ite endpoint BPD-free survival at 36 weeks PMA, these
analyses will not be performed.
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) 2010 flow diagram
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Sensitivity analyses The internationally accepted defin-
ition of the primary outcome BPD is under debate, given
the uncertainty on how to rate continuous positive air-
way pressure (CPAP) or high-flow nasal cannula (HFNC)
with >2 L/minute flow and with low or no supplemental
oxygen [36]. According to the international criteria used,
infants who need this respiratory support should be
rated as having severe BPD [31]. However, the reason
for this support in these very premature infants could be
an impaired control of breathing instead of chronic par-
enchymal lung damage. Therefore, an auxiliary analysis
will be performed in which infants on CPAP and HFNC
in room air will be classified as having mild BPD. If pos-
sible, we will perform sensitivity analyses on the primary
outcome to investigate the impact of correlation be-
tween infant outcomes within twin or higher-order
multiple births using generalised estimating equations
with a logit link function.
Short-term secondary outcomes The effect of HC on
short-term secondary outcomes will be analysed using
linear regression, logistic regression, competing risk
models (that consider death before the event of interest
as a competing risk) or Cox regression models, as appro-
priate. The time to event will be calculated as the time
between randomisation and the event, death, or dis-
charge to home, whichever occurs first. If required, non-
normally distributed continuous variables will be appro-
priately transformed. Only a small number of SUSARs
and SAEs are expected. Hence, these will be evaluated
by tabulations of counts and percentages for each treat-
ment group, respectively, and presented as absolute risk
differences. These outcomes, although all pre-specified,
should be considered exploratory, yielding hypothesis-
generating findings, and so no formal adjustments for
stratification or multiple comparisons will be made.
Long-term outcomes at 2 years corrected age (study phase II)
Neurodevelopmental impairment The key long-term
outcome is survival without neurodevelopmental impair-
ment at 2 years CA. Participants who are alive and have
Table 2 Variables/outcomes to be presented and planned statistical analysis methods
Variable/outcome Type of outcome Statistical analysis
Study phase I: short-term outcomes until initial hospital discharge
BPD-free survival at 36 weeks PMA Primary Logistic regression with correction for stratification factors
plus sensitivity and sub-group analyses
Death at 28 days PNA, at 36 weeks PMA and at hospital discharge
BPD at 36 weeks PMA
Failure to extubate 3, 7, 14 and 21 days after start of trial medication
Time to extubation, censored at death
Time to supplemental oxygen independence
Time to hospital discharge
Necrotising enterocolitis
Gastrointestinal bleeding
Spontaneous intestinal perforation
Intraventricular haemorrhage and/or periventricular leucomalacia
Retinopathy of prematurity
Hypertension
Hyperglycaemia requiring insulin therapy
Nosocomial infection, including clinical or culture-proven sepsis,
meningitis, pneumonia
Patent ductus arteriosus needing medical intervention or surgical
ligation
Weight, head circumference, length at 36 weeks PMA
Use of open-label HC treatment
Short-term
secondary
Linear, logistic or Cox regression or competing risk model,
as appropriate
SUSARs, SAEs Short-term
secondary
Descriptive statistics
Study phase II: long-term follow-up at 2 years CA
Survival without neurodevelopmental impairment Key long-term
secondary
Logistic regression with correction for stratification factors,
sensitivity and sub-group analyses
Mortality
Number of hospital readmissions since first discharge to home
Cerebral palsy and its severity
Hearing loss requiring hearing aids
Blindness
Behaviour problems (Child Behavior Checklist)Growth (weight,
length, head circumference)
Long-term
secondary
Linear, logistic or Cox regression or competing risk model,
as appropriate
Abbreviations: BPD Bronchopulmonary dysplasia, CA Corrected age, HC Hydrocortisone, PMA Postmenstrual age, PNA Postnatal age, SAE Serious adverse event,
SUSAR Suspected unexpected serious adverse drug reaction
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a BSID III cognitive and motor composite score at 2
years CA ≥ 85 will be defined as having survived without
neurodevelopmental impairment. If no BSID III test
could be done because of impairment, the attending
paediatrician was asked to fill in an estimate of cognitive
delay in three categories: no delay, 3–6 months delay or
> 6 months delay. A delay of ≥ 3 months is considered
neurodevelopmental impairment and equivalent to a
BSID III cognitive and motor composite score < 85.
Parents of participants who do not attend the 2-year
assessment at the outpatient clinic will be invited by
telephone once more. If they refuse to attend, the reason
for refusal will be documented. On the basis of available
information about their neurological and developmental
(ab)normality, participants will be classified as having
neurodevelopmental impairment or not, if reasonably
possible. If there is insufficient information to classify the
neurodevelopmental outcome in > 5% of the participants,
missing continuous BSID III scores will be imputed using
multiple imputation using baseline characteristics. As
previously recommended [37], we will obtain a number of
imputed datasets equal to the percentage of missing data.
These datasets will be combined using Rubin’s rules [37, 38].
Inspection and imputation of missing data will be performed
during the blinded review of the data. This strategy will be
updated if, during the blinded data review, unexpected
patterns are detected, requiring an appropriately adapted
handling procedure. In that case, relevant deviations will be
clearly documented and justified. Statistical analysis will be
performed in the same way as for the short-term primary
outcome. If multiple imputation is performed, three add-
itional sensitivity analyses will be performed to test the
robustness of the results obtained. These sensitivity analyses
will be performed (a) using complete cases only and by
applying (b) best case and (c) worst case scenarios for the
unobserved neurodevelopmental impairment outcome data.
Other long-term secondary outcomes The effect of
HC on the other long-term secondary outcomes will be
analysed using linear, logistic or Cox regression or com-
peting risks models, as appropriate. The time to event
will be calculated as the time between randomisation
and the event, death, or 2 years CA, whichever occurs
first. If required, non-normally distributed continuous
variables will be appropriately transformed. These out-
comes, although all pre-specified, should be considered
exploratory, yielding hypothesis-generating findings, and
so no formal adjustments for stratification or multiple
comparisons will be made.
Differences between the study protocol and statistical
analysis plan
We added the AT analysis, thus creating a group that did
not receive corticosteroids and a group that did receive
corticosteroids, to check the robustness of the main ana-
lyses in the ITT population. We clarified that the interim
analyses were performed solely to highlight safety issues
and that there was no intention to stop the trial early for
efficacy. This was to maintain power for the neurodeve-
lopmental outcome at 2 years CA. We also clarified how
the analyses would be performed and how stratification
factors would be included in the analyses.
Trial status
Initially, 15 participating centres started recruitment
between December 2011 and July 2012, and 4 additional
centres started recruitment in 2015. Recruitment
stopped on 31 December 2016, and the last assessment
of the primary outcome was completed by March 2017.
The last follow-up at 2 years CA is expected around
March 2019. Before the data are analysed, the database
will be cleaned and checked for completeness and
internal consistency, blinded to treatment allocation.
The database will be locked only after this SAP has been
submitted for publication in a peer-reviewed journal.
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